文献速递淋巴瘤

局限期浆母细胞淋巴瘤患者的结局:一项多机构回顾性研究

Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study.
PubMed 文献 · Am J Hematol · 2023-01-01

该多机构回顾性研究纳入来自美国13个学术中心的80例I或II期浆母细胞淋巴瘤患者,中位随访34个月,全队列3年无进展生存率为72%(95%CI 62,83),总生存率为79%(95%CI 70,89);接受EPOCH为基础的一线治疗者较CHOP方案无进展生存改善(HR: 0.23;p=0.029)。

要点

  • 局限期浆母细胞淋巴瘤全队列3年无进展生存率为72%,总生存率为79%。
  • 接受EPOCH为基础一线治疗者较CHOP方案无进展生存改善(HR: 0.23;p=0.029)。
  • 强化一线治疗包括Hyper-CVAD或自体干细胞移植巩固未见结局改善。

核心结论

  • 局限期浆母细胞淋巴瘤患者结局较好,强化一线治疗包括Hyper-CVAD或自体干细胞移植巩固未见结局改善。
  • 多因素回归分析显示,接受EPOCH为基础一线治疗者较CHOP方案无进展生存改善(HR: 0.23;p=0.029)。
  • 一线化疗后放疗巩固与单纯化疗相比似乎与改善的复发和生存结局相关,但在多因素回归分析中未显示统计学显著性。

研究设计与样本

  • 多机构回顾性研究,纳入来自美国13个学术中心的80例I或II期浆母细胞淋巴瘤患者。

主要发现

  • 中位随访34个月(范围1-196),全队列3年无进展生存率为72%(95%CI 62,83),总生存率为79%(95%CI 70,89)。
  • 多因素回归分析显示,接受EPOCH为基础一线治疗者较CHOP方案无进展生存改善(HR: 0.23;p=0.029)。

关键数值与推荐

  • 全队列3年无进展生存率为72%(95%CI 62,83),总生存率为79%(95%CI 70,89)。
  • EPOCH为基础一线治疗对比CHOP方案的无进展生存风险比HR为0.23(p=0.029)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Plasmablastic lymphoma (PBL) is a rare entity, commonly associated with immunosuppressed states such as human immunodeficiency virus (HIV) infection or solid organ transplant. The clinical course is characterized by high relapse rates and a poor prognosis, leading some clinicians to recommend aggressive frontline therapy. However, a specific review of limited stage (LS) PBL patients is not available to evaluate outcomes and justify treatment recommendations. We performed a retrospective review of LS PBL cases to provide insight into this rare disease. Our cohort consisted of 80 stage I or II PBL patients from 13 US academic centers. With a median follow up of 34 months (1-196), the 3-year progression-free survival (PFS) and overall survival (OS) of the entire cohort were 72% (95% CI 62, 83) and 79% (95% CI 70, 89), respectively. The 3-year PFS and OS of patients treated with frontline chemotherapy alone was 65% (95% CI 50, 84) and 71% (95% CI 56, 89), respectively, compared to 85% (95% CI 72, 100) and 96% (95% CI 89, 100), respectively, in patients treated with combined frontline chemotherapy with radiation consolidation. Our data demonstrate favorable outcomes in LS PBL with no improvements in outcome from aggressive frontline treatment including Hyper-CVAD or auto-SCT consolidation. Multivariate regression analysis (MRA) demonstrated improved PFS for patients receiving EPOCH based frontline therapy versus CHOP (HR: 0.23; p = 0.029). Frontline chemotherapy followed by radiation consolidation versus chemotherapy alone appeared to be associated with improved relapse and survival outcomes but did not show statistical significance in MRA.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Hess BT, Giri A, Park Y, et al. Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study. Am J Hematol. 2023. PMID: 36588409. doi:10.1002/ajh.26784

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。